GlassScriptPhysician profile
Timothy D Wagner
NPI 1619169935
$1,567.38
in general payments reported to CMS, 2019-2025
26 companies · $704 in 2025
The $704 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $179 · 2024: $684 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $263.97 | 2025 | Xt Cdx |
| Siemens Medical Solutions USA, INC. | $157.12 | 2023 | Varian Ethos Treatment Planning |
| Astrazeneca Pharmaceuticals LP | $127.76 | 2024-2025 | Tagrisso, Imfinzi, Enhertu |
| Myriad Genetic Laboratories, INC. | $95.87 | 2024 | Myrisk |
| Janssen Biotech, INC. | $84.77 | 2025 | Darzalex, Talvey, Tecvayli |
| Aveo Pharmaceuticals, INC. | $81.34 | 2024-2025 | |
| Incyte Corporation | $79.93 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $64.64 | 2024-2025 | Libtayo |
| Lilly USA, LLC | $63.93 | 2024 | Verzenio, Jaypirca |
| Sobi, INC | $51.15 | 2024 | |
| Pfizer INC. | $50.55 | 2024 | |
| Pharmacosmos Therapeutics INC. | $49.41 | 2024-2025 | Monoferric |
| Boston Scientific Corporation | $46.57 | 2025 | General - Therapies, Therasphere Y90 Glass Microspheres 10 Gbq |
| Taiho Oncology, INC. | $45.42 | 2024 | |
| Tersera Therapeutics LLC | $35.72 | 2025 | Xermelo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $35.44 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $31.20 | 2024 | Xarelto, Darzalex, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $28.64 | 2025 | |
| Daiichi Sankyo INC. | $28.37 | 2024 | Enhertu |
| Novocure INC. | $26.12 | 2025 | Optune Gio |
| Array Biopharma INC | $25.39 | 2024 | Braftovi, Mektovi, Tukysa |
| Sumitomo Pharma America, INC. | $23.79 | 2024 | Orgovyx |
| Agile Therapeutics, INC. | $22.07 | 2023 | Twirla |
| Alcresta Therapeutics, INC. | $19.04 | 2024 | Relizorb |
| Azurity Pharmaceuticals, INC. | $14.90 | 2024 | Vivimusta |
| Tactile Systems Technology INC | $14.27 | 2024 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.